Please use this identifier to cite or link to this item:
Title: Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.
Authors: Rodgers, M
Epstein, D
Bojke, L
Yang, H
Craig, D
Fonseca, T
Myers, L
Bruce, I
Chalmers, R
Bujkiewicz, S
Lai, M
Cooper, N
Abrams, K
Spiegelhalter, D
Sutton, A
Sculpher, M
Woolacott, N
First Published: Feb-2011
Citation: HEALTH TECHNOL ASSESS, 2011, 15 (10), pp. i-329
Abstract: Etanercept, infliximab and adalimumab are licensed in the UK for the treatment of active and progressive psoriatic arthritis (PsA) in adults who have an inadequate response to standard treatment.
DOI Link: 10.3310/hta15100
ISSN: 1366-5278
Type: Journal Article
Appears in Collections:Published Articles, Dept. of Health Sciences

Files in This Item:
There are no files associated with this item.

Items in LRA are protected by copyright, with all rights reserved, unless otherwise indicated.